Conclusion: Patients with normal serum HER-2/neu receiving letrozole demonstrated a significantly greater ORR and CB and longer TTP and TTF than patients receiving tamoxifen. Although in patients with ...
CONCLUSION: The majority of patients with HER-2/neu–overexpressing cancers can develop immunity to both HER-2/neu peptides and protein. In addition, the generation of protein-specific immunity, after ...
Breast Tumor Section showing nonamplified HER-2/neu (<4 signals/nucleus). Cells are stained with DAPI. Probe is detected with flurorescein. There is perhaps nothing more disturbing to a woman than a ...
TUCSON, Ariz., Nov. 25, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. Food and Drug Administration (FDA) approval of a label expansion into biliary tract cancer (BTC ...
Human epidermal growth factor receptor 2 (HER2)/neu overexpression, amplification and mutations are associated with an increased metastatic potential in cancer cells and poor prognosis. HER2 signaling ...
The highest rates of HER2 positivity were observed in bladder cancer, uterine serous carcinoma, and esophagogastric junction cancer. New research suggests the incidence of HER2 positivity is low ...
If you have HER2-positive breast cancer, your options for treatment will depend on several factors, such as the stage of cancer (early or metastatic) and the hormone receptor status of the tumor. HER2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback